AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35472672 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg or 25 mg daily
Number of subjects: 15081
Study 35472672 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15081
Study 32167978 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine 0.12 mg/kg/h
Number of subjects: 198
Study 32167978 — intervention group
Group type: EXPERIMENTAL
Intervention: S-ketamine 0.6 mg/kg/h
Number of subjects: 198
Study 32167978 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline 0.9%)
Number of subjects: 198
Study 35662230 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative wound management pathway (details not specified)
Number of subjects: 58
Study 33069511 — intervention group
Group type: COMPARATOR
Intervention: Basmati rice (CONTROL)
Number of subjects: 24
Study 33069511 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled potato (BOIL)
Number of subjects: 24
Study 33069511 — intervention group
Group type: EXPERIMENTAL
Intervention: Roasted potato (ROAST)
Number of subjects: 24
Study 33069511 — intervention group
Group type: EXPERIMENTAL
Intervention: Boiled potato cooled for 24 hours (COOLED)
Number of subjects: 24
Study 33069511 — intervention group
Group type: EXPERIMENTAL
Intervention: All potato meals
Number of subjects: 24
Study 36225251 — intervention group
Group type: EXPERIMENTAL
Intervention: ESPB group (preoperative ultrasound‐guided lumbar ESPB)
Number of subjects: 63
Study 36225251 — intervention group
Group type: COMPARATOR
Intervention: Control group (spinal alone)
Number of subjects: 63
Study 36225251 — intervention group
Group type: EXPERIMENTAL
Intervention: ESPB group
Number of subjects: 63
Study 36225251 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 63
Study 33326257 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib (320 mg twice daily, 4 days on/3 days off)
Number of subjects: 150
Study 33326257 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 33326257 — intervention group
Group type: EXPERIMENTAL
Intervention: Capivasertib and Placebo
Number of subjects: 150
Study 34702621 — intervention group
Group type: EXPERIMENTAL
Intervention: aTIV
Number of subjects: 424
Study 34702621 — intervention group
Group type: COMPARATOR
Intervention: QIV
Number of subjects: 424
Study 35920686 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen treatment
Number of subjects: 394
Study 32860422 — intervention group
Group type: EXPERIMENTAL
Intervention: Esketamine nasal spray + oral antidepressant (AD)
Number of subjects: 100
Study 32860422 — intervention group
Group type: COMPARATOR
Intervention: AD + placebo
Number of subjects: 100
Study 33838678 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent Positive
Number of subjects: 616
Study 33838678 — intervention group
Group type: COMPARATOR
Intervention: Follow-up As Usual (FAU)
Number of subjects: 616
Study 33169306 — intervention group
Group type: EXPERIMENTAL
Intervention: RCC < 2 cm
Number of subjects: 43147
Study 33169306 — intervention group
Group type: COMPARATOR
Intervention: RCC 2.1–4 cm
Number of subjects: 43147
Study 32795428 — intervention group
Group type: EXPERIMENTAL
Intervention: Levonorgestrel-releasing intrauterine system (Mirena)
Number of subjects: 270
Study 32795428 — intervention group
Group type: COMPARATOR
Intervention: Endometrial ablation (NovaSure)
Number of subjects: 270
Study 32195937 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise program (aerobic and resistance training), 48 sessions over 16 weeks (3 sessions/week, 60 min/session)
Number of subjects: 40
Study 32195937 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical exercise program (aerobic and resistance training)
Number of subjects: 40
Study 32195937 — intervention group
Group type: COMPARATOR
Intervention: Lifestyle recommendations (Control group)
Number of subjects: 40
Study 34811807 — intervention group
Group type: EXPERIMENTAL
Intervention: Depressive symptomatology (PHQ‐9 score ≥ 10)
Number of subjects: 3356
Study 34811807 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthreshold depressive symptomatology (PHQ‐9 score 5‐9 and at least one core depressive symptom)
Number of subjects: 3356
Study 34811807 — intervention group
Group type: COMPARATOR
Intervention: Female gender, low socioeconomic conditions, and presence of chronic conditions
Number of subjects: 3356
Study 34811807 — intervention group
Group type: COMPARATOR
Intervention: Female gender and having hypertension
Number of subjects: 3356
Study 36066336 — intervention group
Group type: EXPERIMENTAL
Intervention: Turmeric mouthwash
Number of subjects: 92
Study 36066336 — intervention group
Group type: COMPARATOR
Intervention: Benzydamine mouthwash
Number of subjects: 92
Study 33537844 — intervention group
Group type: EXPERIMENTAL
Intervention: Romosozumab
Number of subjects: 0
Study 33537844 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 32433790 — intervention group
Group type: EXPERIMENTAL
Intervention: Near-focus narrowband imaging (NF‐NBI)
Number of subjects: 395
Study 32433790 — intervention group
Group type: COMPARATOR
Intervention: Indigo carmine chromoendoscopy (ICC)
Number of subjects: 395
Study 35759637 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous tranexamic acid (1 g)
Number of subjects: 141
Study 35759637 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous tranexamic acid (1 g)
Number of subjects: 141
Study 35759637 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 141
Study 32041440 — intervention group
Group type: EXPERIMENTAL
Intervention: Intense Pulsed Light (IPL)
Number of subjects: 0
Study 32041440 — intervention group
Group type: COMPARATOR
Intervention: Pulsed Dye Laser (PDL)
Number of subjects: 0
Study 36335059 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflexology
Number of subjects: 156
Study 36335059 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 156
Study 33921829 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus plantarum CJLP55 supplement
Number of subjects: 28
Study 33921829 — intervention group
Group type: COMPARATOR
Intervention: Placebo supplement
Number of subjects: 28
Study 33038271 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2 g/kg alcohol dose
Number of subjects: 61
Study 33038271 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.8 g/kg alcohol dose
Number of subjects: 61
Study 33038271 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.0 g/kg alcohol dose
Number of subjects: 61
Study 35448206 — intervention group
Group type: EXPERIMENTAL
Intervention: FORT RCT
Number of subjects: 15
Study 33975304 — intervention group
Group type: EXPERIMENTAL
Intervention: Social Nutrition Program (additional 27 g of protein/day and social network intervention)
Number of subjects: 150
Study 33975304 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 150
Study 32672800 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab, 0.5 mg, plus verteporfin photodynamic therapy (vPDT)
Number of subjects: 322
Study 32672800 — intervention group
Group type: COMPARATOR
Intervention: Ranibizumab, 0.5 mg, plus sham PDT
Number of subjects: 322
Study 36377145 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic Percutaneous Extra-peritoneal Closure (LPEC)
Number of subjects: 296
Study 36377145 — intervention group
Group type: COMPARATOR
Intervention: Open Repair
Number of subjects: 296
Study 32349041 — intervention group
Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii
Number of subjects: 0
Study 32349041 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus GG
Number of subjects: 0
Study 32349041 — intervention group
Group type: EXPERIMENTAL
Intervention: L reuteri DSM 17938
Number of subjects: 0
Study 32349041 — intervention group
Group type: EXPERIMENTAL
Intervention: L rhamnosus 19070‐2
Number of subjects: 0
Study 32349041 — intervention group
Group type: EXPERIMENTAL
Intervention: L reuteri DSM 12246
Number of subjects: 0
Study 32349041 — intervention group
Group type: COMPARATOR
Intervention: L helveticus R0052
Number of subjects: 0
Study 32349041 — intervention group
Group type: COMPARATOR
Intervention: L rhamnosus R0011
Number of subjects: 0
Study 32349041 — intervention group
Group type: COMPARATOR
Intervention: Bacillus clausii strains O/C, SIN, N/R, and T
Number of subjects: 0
Study 32071176 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo treatment with treatment rationale
Number of subjects: 150
Study 32071176 — intervention group
Group type: EXPERIMENTAL
Intervention: Open-label placebo treatment without treatment rationale
Number of subjects: 150
Study 32071176 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 150
Study 33964104 — intervention group
Group type: EXPERIMENTAL
Intervention: Local probiotics applied to periodontal pocket after scaling and root planning (SRP)
Number of subjects: 80
Study 33964104 — intervention group
Group type: COMPARATOR
Intervention: Scaling and root planning (SRP) only
Number of subjects: 80
Study 32000743 — intervention group
Group type: EXPERIMENTAL
Intervention: Sun protection intervention involving presentation, action planning, and SMS messages.
Number of subjects: 487
Study 34731434 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupoint injection combined with CSEA plus PCEA (AICP group, n=168)
Number of subjects: 307
Study 34731434 — intervention group
Group type: COMPARATOR
Intervention: CSEA plus PCEA (CP group, n=139)
Number of subjects: 307
Study 34080789 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) administration via intravenous and dorsal pancreatic arterial routes
Number of subjects: 30
Study 34080789 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous bone marrow-derived mesenchymal stem/stromal cells (BM-MSCs) administration
Number of subjects: 30
Study 36081312 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week tongue elevation training program consisting of anterior tongue elevation strength and endurance tasks with the Iowa Oral Performance Instrument.
Number of subjects: 27
Study 36081312 — intervention group
Group type: COMPARATOR
Intervention: 6-week sham training protocol involving expiratory muscle training at very low intensity.
Number of subjects: 27
Study 33902778 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up study after COVID-19 pandemic
Number of subjects: 207
Study 36478462 — intervention group
Group type: EXPERIMENTAL
Intervention: Aluminium pancakes
Number of subjects: 15
Study 36478462 — intervention group
Group type: COMPARATOR
Intervention: Placebo pancakes
Number of subjects: 15
Study 34429074 — intervention group
Group type: EXPERIMENTAL
Intervention: Impairment-based care plus PEERC
Number of subjects: 94
Study 34429074 — intervention group
Group type: COMPARATOR
Intervention: Impairment-based care
Number of subjects: 94
Study 35253061 — intervention group
Group type: EXPERIMENTAL
Intervention: Triage bracelets
Number of subjects: 11
Study 35253061 — intervention group
Group type: COMPARATOR
Intervention: No triage bracelets (control)
Number of subjects: 11
Study 33234910 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone app reminder for ASA adherence (81 mg twice daily for 35 days)
Number of subjects: 195
Study 33234910 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 195
Study 36182909 — intervention group
Group type: EXPERIMENTAL
Intervention: Health education intervention provided by trained health professionals using power point presentation and peer group discussion for three days followed by consultations for 6 months.
Number of subjects: 700
Study 34193677 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation for 12 weeks
Number of subjects: 18
Study 34193677 — intervention group
Group type: EXPERIMENTAL
Intervention: BCAA supplementation
Number of subjects: 18
Study 32615487 — intervention group
Group type: EXPERIMENTAL
Intervention: Short MHL Program (SMHLP)
Number of subjects: 975
Study 32615487 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 975
Study 36124619 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbations with one stride or less of response time
Number of subjects: 13
Study 36124619 — intervention group
Group type: EXPERIMENTAL
Intervention: Perturbations with two strides of response time
Number of subjects: 13
Study 36124619 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictable physical nature of the perturbation
Number of subjects: 13
Study 33075419 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the hand motor hotspot (hMHS)
Number of subjects: 10
Study 33075419 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 Hz rTMS over the anatomical hand knob (HK)
Number of subjects: 10
Study 33075419 — intervention group
Group type: COMPARATOR
Intervention: Sham-rTMS
Number of subjects: 10
Study 36331513 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion (RME)
Number of subjects: 72
Study 36331513 — intervention group
Group type: COMPARATOR
Intervention: Quad Helix (QH)
Number of subjects: 72
Study 36331513 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RME and QH
Number of subjects: 72
Study 34402328 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim administration <20 hours after chemotherapy
Number of subjects: 182
Study 34402328 — intervention group
Group type: COMPARATOR
Intervention: Pegfilgrastim administration ≥24 hours after chemotherapy
Number of subjects: 182
Study 34402328 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of pegfilgrastim administration (earlier or later than 20 hours)
Number of subjects: 182
Study 34402328 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall outcomes of pegfilgrastim administration
Number of subjects: 182
Study 35449997 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency anemia (IDA) group
Number of subjects: 190
Study 35449997 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron deficiency (ID) group
Number of subjects: 190
Study 35449997 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 190
Study 35449997 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall comparison among groups
Number of subjects: 190
Study 35449997 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 190
Study 32108322 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal injection of plasma gel
Number of subjects: 60
Study 32108322 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermaroller
Number of subjects: 60
Study 32108322 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined plasma gel and dermaroller
Number of subjects: 60
Study 35266048 — intervention group
Group type: EXPERIMENTAL
Intervention: Telestration with augmented reality (AR) during training
Number of subjects: 60
Study 32467635 — intervention group
Group type: EXPERIMENTAL
Intervention: tropicamide (1%)
Number of subjects: 95
Study 32467635 — intervention group
Group type: EXPERIMENTAL
Intervention: tropicamide (0.5%) + phenylephrine (10%)
Number of subjects: 95
Study 32467635 — intervention group
Group type: COMPARATOR
Intervention: Control group receiving artificial tears
Number of subjects: 95
Study 35022498 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperspectral imaging (HSI)
Number of subjects: 21
Study 35346971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention integrated into DSMES plus one booster session and 24 weeks of home practice supported by a mobile application
Number of subjects: 132
Study 35346971 — intervention group
Group type: COMPARATOR
Intervention: Comprehensive DSMES group session (control)
Number of subjects: 132
Study 35346971 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 132
Study 35346971 — intervention group
Group type: COMPARATOR
Intervention: Mindfulness intervention and control
Number of subjects: 132
Study 32074767 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole 7.5 mg daily for 3 days
Number of subjects: 99
Study 32074767 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist (cetrorelix 0.25 mg subcutaneously daily for 3 days)
Number of subjects: 99
Study 32074767 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole
Number of subjects: 99
Study 32074767 — intervention group
Group type: COMPARATOR
Intervention: GnRH antagonist
Number of subjects: 99
Study 32074767 — intervention group
Group type: EXPERIMENTAL
Intervention: Letrozole and GnRH antagonist
Number of subjects: 99
Study 36001712 — intervention group
Group type: EXPERIMENTAL
Intervention: Olokizumab every 2 weeks
Number of subjects: 464
Study 36001712 — intervention group
Group type: EXPERIMENTAL
Intervention: Olokizumab every 4 weeks
Number of subjects: 464
Study 36001712 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 464
Study 36001712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 464
Study 36001712 — intervention group
Group type: COMPARATOR
Intervention: Olokizumab every 2 weeks vs. Adalimumab
Number of subjects: 464
Study 36001712 — intervention group
Group type: COMPARATOR
Intervention: Olokizumab every 4 weeks vs. Adalimumab
Number of subjects: 464
Study 33124472 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute psychosocial stressor
Number of subjects: 164
Study 33124472 — intervention group
Group type: COMPARATOR
Intervention: Non-stressful control condition
Number of subjects: 164
Study 33161844 — intervention group
Group type: EXPERIMENTAL
Intervention: NOTCH3 cysteine altering variants
Number of subjects: 118
Study 33161844 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nonsynonymous variants in NOTCH3)
Number of subjects: 118
Study 34555200 — intervention group
Group type: EXPERIMENTAL
Intervention: 11 for Health in Denmark program (IG)
Number of subjects: 1122
Study 32925992 — intervention group
Group type: COMPARATOR
Intervention: CaOH2 only
Number of subjects: 18
Study 32925992 — intervention group
Group type: EXPERIMENTAL
Intervention: CaOH2+EMD
Number of subjects: 18
Study 32925992 — intervention group
Group type: EXPERIMENTAL
Intervention: CaOH2+rhPDGF
Number of subjects: 18
Study 34371898 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet (MD)
Number of subjects: 120
Study 34371898 — intervention group
Group type: COMPARATOR
Intervention: Low-Fat Diet (LFD)
Number of subjects: 120
Study 32553536 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 239
Study 32553536 — intervention group
Group type: COMPARATOR
Intervention: Severe disease (control)
Number of subjects: 239
Study 33077900 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D head-mounted virtual reality (HMD VR)
Number of subjects: 16
Study 35105809 — intervention group
Group type: EXPERIMENTAL
Intervention: Text reminders encouraging flu vaccination
Number of subjects: 689693
Study 35105809 — intervention group
Group type: EXPERIMENTAL
Intervention: Text reminders reminding patients that a flu shot was waiting for them
Number of subjects: 689693
Study 35105809 — intervention group
Group type: COMPARATOR
Intervention: Business-as-usual control condition (no messages)
Number of subjects: 689693
Study 33398561 — intervention group
Group type: EXPERIMENTAL
Intervention: pSOC using the SpyGlass™ DS system
Number of subjects: 28
Study 32013614 — intervention group
Group type: COMPARATOR
Intervention: Saffron supplementation
Number of subjects: 0
Study 32013614 — intervention group
Group type: COMPARATOR
Intervention: Crocin supplementation
Number of subjects: 0
Study 32013614 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35272268 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyostimulation (EMS) of the peroneus longus muscle, 3 times per week for 5 weeks, each session lasting 25 minutes.
Number of subjects: 32
Study 35272268 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 32
Study 34682601 — intervention group
Group type: EXPERIMENTAL
Intervention: Calls
Number of subjects: 1680
Study 34682601 — intervention group
Group type: COMPARATOR
Intervention: Texts
Number of subjects: 1680
Study 32134436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery with clear intraocular lens (IOL)
Number of subjects: 169
Study 32134436 — intervention group
Group type: EXPERIMENTAL
Intervention: Cataract surgery with yellow intraocular lens (IOL)
Number of subjects: 169
Study 33095737 — intervention group
Group type: EXPERIMENTAL
Intervention: Online semisupervised active learning framework (OSAM) for multiview PolSAR data classification
Number of subjects: 0
Study 34017098 — intervention group
Group type: EXPERIMENTAL
Intervention: Visuospatial working memory training
Number of subjects: 17648
Study 34017098 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial, non-verbal reasoning training
Number of subjects: 17648
Study 34017098 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental rotation or tangram tasks
Number of subjects: 17648
Study 34031487 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D model
Number of subjects: 248
Study 34031487 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D model
Number of subjects: 248
Study 34031487 — intervention group
Group type: EXPERIMENTAL
Intervention: 2D model for viral hepatitis, cholestatic cirrhosis, and NASH-associated cirrhosis
Number of subjects: 248
Study 34031487 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D model for alcoholic cirrhosis
Number of subjects: 248
Study 34031487 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intra-class correlation coefficient (ICC) for 2D measurements
Number of subjects: 248
Study 34031487 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intra-class correlation coefficient (ICC) for 3D measurements
Number of subjects: 248
Study 32487264 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct Anterior Approach (DAA)
Number of subjects: 130
Study 32487264 — intervention group
Group type: COMPARATOR
Intervention: Posterolateral Approach (PLA)
Number of subjects: 130
Study 34253678 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle and Empowerment Techniques (LETSGO study) involving patient education, psychosocial support, and promotion of physical activity through a smartphone application for monitoring symptoms and promoting physical activity.
Number of subjects: 0
Study 34253678 — intervention group
Group type: COMPARATOR
Intervention: Standard follow-up programme at control hospitals.
Number of subjects: 0
Study 36180610 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (subcutaneous) for osteoporosis, 5 years continuous treatment
Number of subjects: 1
Study 36180610 — intervention group
Group type: EXPERIMENTAL
Intervention: Denosumab (subcutaneous) for osteoporosis
Number of subjects: 1